Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P. Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2017;96:e6983.
Google Scholar
Kim D, Cho SK, Choi CB, Jun JB, Kim TH, Lee HS, et al. Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. Rheumatol Int. 2016;36:1205–14.
PubMed
Google Scholar
Vis M, Haavardsholm EA, Boyesen P, Haugeberg G, Uhlig T, Hoff M, et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int. 2011;22:2413–9.
CAS
PubMed
PubMed Central
Google Scholar
Ochi K, Inoue E, Furuya T, Ikari K, Toyama Y, Taniguchi A, et al. Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture. Osteoporos Int. 2015;26:961–8.
CAS
PubMed
Google Scholar
Omata Y, Hagiwara F, Nishino J, Matsudaira K, Kadono Y, Juji T, et al. Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients. J Bone Miner Metab. 2014;32:725–31.
PubMed
Google Scholar
Baillet A, Gossec L, Carmona L, Wit M, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016;75:965–73.
PubMed
Google Scholar
Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother. 2015;16:559–71.
CAS
Google Scholar
Raterman HG, Bultink IEM, Lems WF. Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs. 2019;79:1065–87.
CAS
PubMed
Google Scholar
Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Anno S, et al. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study. Rheumatol Int. 2017;37:999–1005.
CAS
PubMed
Google Scholar
Kaneko T, Okamura K, Yonemoto Y, Okura C, Suto T, Tachibana M, et al. Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates. J Exp Orthop. 2019;6:41.
PubMed
PubMed Central
Google Scholar
Ebina K, Hirao M, Hashimoto J, Hagihara K, Kashii M, Kitaguchi K, et al. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis. J Bone Miner Metab. 2018;36:478–87.
CAS
PubMed
Google Scholar
Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int. 2014;25:2755–65.
CAS
PubMed
Google Scholar
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–39.
CAS
Google Scholar
El Maghraoui A, Rezqi A, Mounach A, Achemlal L, Bezza A, Ghozlani I. Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis using vertebral fracture assessment. Rheumatology (Oxford). 2010;49:1303–10.
Google Scholar
Filho JC, Pinheiro MM, de Moura Castro CH, Szejnfeld VL. Prevalence and risk factors associated with low-impact fractures in men with rheumatoid arthritis. Clin Rheumatol. 2014;33:1389–95.
PubMed
Google Scholar
Ishida O, Furuya T, Inoue E, Ochi K, Ikari K, Taniguchi A, et al. Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: results from a large prospective observational cohort study. Mod Rheumatol. 2015;25:373–8.
CAS
PubMed
Google Scholar
Furuya T, Inoue E, Hosoi T, Taniguchi A, Momohara S, Yamanaka H. Risk factors associated with the occurrence of hip fracture in Japanese patients with rheumatoid arthritis: a prospective observational cohort study. Osteoporos Int. 2013;24:1257–65.
CAS
PubMed
Google Scholar
Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Hara M, et al. Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study. J Bone Miner Metab. 2008;26:499–505.
PubMed
Google Scholar
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
PubMed
Google Scholar
Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337–50.
Google Scholar
Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging. 2007;24:37–55.
CAS
Google Scholar
Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos. 2015;10:231.
PubMed
Google Scholar
Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.
CAS
Google Scholar
Guler H, Turhanoglu AD, Ozer B, Ozer C, Balci A. The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol. 2008;37:337–42.
CAS
PubMed
Google Scholar
Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1997;24:1489–94.
CAS
PubMed
Google Scholar
Torikai E, Kageyama Y, Takahashi M, Nagano A. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. Mod Rheumatol. 2006;16:350–4.
CAS
PubMed
Google Scholar
Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, et al. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken). 2015;67:754–64.
CAS
Google Scholar
Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther. 2019;21:255.
CAS
PubMed
PubMed Central
Google Scholar
Oguro N, Yajima N, Miwa Y. Age and quality of life in patients with rheumatoid arthritis treated with biologic agents. Mod Rheumatol. 2020;30:44–9.
PubMed
Google Scholar
Kwon HY, Kim HH, Sung YK, Ha YC. Incidence and mortality of osteoporotic fracture in rheumatoid arthritis in South Korea using nationwide claims data. J Bone Metab. 2019;26:97–104.
PubMed
PubMed Central
Google Scholar
Katayama K, Matsuno T. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study. Clin Drug Investig. 2008;28:149–58.
CAS
PubMed
Google Scholar
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.
CAS
Google Scholar
van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.
Google Scholar
Chen H, Lips P, Vervloet MG, van Schoor NM, de Jongh RT. Association of renal function with bone mineral density and fracture risk in the longitudinal aging study Amsterdam. Osteoporos Int. 2018;29:2129–38.
CAS
PubMed
PubMed Central
Google Scholar
Xie Z, Liu G, Tang P, Sun X, Chen S, Qin A, et al. Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo. Drug Deliv. 2018;25:187–97.
CAS
PubMed
PubMed Central
Google Scholar
Le Goff B, Soltner E, Charrier C, Maugars Y, Redini F, Heymann D, et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther. 2009;11:R185.
PubMed
PubMed Central
Google Scholar
Xie J, Li S, Xiao L, Ouyang G, Zheng L, Gu Y, et al. Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. J Orthop Surg Res. 2019;14:421.
PubMed
PubMed Central
Google Scholar
Shao F, Li HC, Wang MJ, Cui CM. Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25:3416–24.
CAS
PubMed
Google Scholar
Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Yamanaka H, et al. Vitamin D deficiency is a risk factor for new fractures in Japanese postmenopausal women with rheumatoid arthritis: results from the IORRA cohort study. Arch Osteoporos. 2021;16:119.
PubMed
Google Scholar
Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res. 1996;11:1531–8.
CAS
Google Scholar
Ivaska KK, Gerdhem P, Väänänen HK, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res. 2010;25:393–403.
CAS
PubMed
Google Scholar
Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M, et al. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporos Int. 2016;27:351–9.
CAS
PubMed
Google Scholar
Kumagai K, Harigane K, Kusayama Y, Tezuka T, Inaba Y, Saito T. Total knee arthroplasty improves both knee function and disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27:806–10.
PubMed
Google Scholar